Replidyne's Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium... (eases. Inpreclinical studies REP3123 has...)

Replidyne's Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile

Date:9/19/2007

eases. In preclinical studies, REP3123 has been show to inhibit growth, toxin production and spore-forming in C. difficile bacteria. Replidyne is also pursuing the development of other novel anti-infective programs based on its in-house discovery research.

Safe Harbor

This press release contains plans, intentions, objectives, estimates and expectations that constitute forward-looking statements about Replidyne, Inc. that involve significant risks and uncertainties. Actual results could differ materially from those discussed due to a number of factors including, the success and timing of pre-clinical studies and clinical trials; the Company's ability to obtain a new partner for faropenem on acceptable terms; the Company's ability to obtain and maintain regulatory approval of product candidates and the labeling under any approval that may be obtained; plans to develop and commercialize product candidates; the loss of key scientific or management personnel; the size and growth of the potential markets for the Company's product candidates and the Company's ability to serve those markets; regulatory developments in the U.S. and foreign countries; the rate and degree of market acceptance of any future products; the accuracy of Company estimates regarding expenses, future revenues and capital requirements; the Company's ability to obtain and maintain intellectual property protection for our product candidates; the successful development of the Company's sales and marketing capabilities; the success of competing drugs that are or become available; and the performance of third party manufacturers. These and additional risks and uncertainties are described more fully in the Company's most recent Form 10-Q filed with the SEC under the Securities Exchange Act of 1934. Copies of filings made with the SEC are available through the SEC's electronic data gather analysis and retrieval system (EDGAR) at http://www.sec.gov. Al
'/>"/>

SOURCE Replidyne, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents

Post Your Comments:

(Date:12/15/2009)... OBP Medical Inc. declares victory in the battle ... hospitals. ,, Doctors at Newton-Wellesley Hospital in Newton, ... Medical,s Under Johnnies(TM) on patients, comfort and satisfaction ... is comparing patients, perception of comfort, privacy and ... Johnnies(TM) against the traditional hospital gown and socks. ...

(Date:12/14/2009)... Dec. 14 Embarrassing and sometimes uncomfortable colonoscopies ... National researchers are taking note of a new screening ... process. The Knoxville-based company, EDP Biotech Corporation ... ColoMarker, an affordable medical device doctors can use to ... "When you consider that 30% of colon cancer ...

(Date:12/14/2009)... 14 The board of directors of Eli ... declared a dividend for the first quarter of 2010 ... ,, The dividend is payable March 10, 2010 ... on ,, February 12, 2010. ,, Lilly, a ... pharmaceutical products by applying the latest research from its ...

[0] Under Johnnies(TM) Proven To Increase Patient Satisfaction by OBP Medical Inc.[0] EDP Biotech Takes Next Step in the Development of ColoMarker [0] Lilly Declares First-Quarter 2010 Dividend

... Vical Incorporated (Nasdaq:,VICL) today reported financial results for ... quarter of 2007 were $3.1 million, compared with,revenues of ... net loss for,the second quarter of 2007 was $8.2 ... of $3.2 million, or $0.11 per share, for the ...

... Progression Rates Are the ... Resources, WALTHAM, Mass., Aug. 7 Decision ... advisory firms focusing on pharmaceutical,and healthcare issues, finds ... Sutent as the clinical gold standard for,the treatment ...

Other Medicine Technology:Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 2 Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 3 Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 4 Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 5 Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 6 Wyeth's Torisel and Roche/Genentech's Avastin Will Challenge Pfizer's Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma 2

Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs Wyeth's Torisel and Roche/Genentech's Avastin Will Challenge Pfizer's Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma

(Date:12/14/2009)... and more… , ... Santa Barbara, ... with scientists at University of Michigan, have developed synthetic particles ... red blood cells, including softness, flexibility, and the ability to ... of natural red blood cells is to carry oxygen, and ...

(Date:12/14/2009)... -- Americold Realty Trust ("Americold") announced today that it ... the U.S. Securities and Exchange Commission (the "SEC") relating ... shares. The number of shares to be offered and ... been determined. The common shares to be sold in ... ,, The joint book-running managers of the offering ...

(Date:12/14/2009)... Organization for Rare Disorders (NORD) today called upon Congress ... health insurance caps. In a full-page ad in ... Capitol Hill, NORD said the current Senate health reform ... for most Americans, contrary to what many people believe. ... the promises made by President Obama and Congress to ...

(Date:12/14/2009)... replaced tube watching , , MONDAY, Dec. 14 (HealthDay News) ... of television a week until he enrolled in a ... in half. , During his enforced period of deprivation, ... necessarily through strenuous exercise, although he did find his ... was spent reading and working on the computer, said ...

(Date:12/14/2009)... Ohio, Dec. 14 Skilled nursing facilities (SNFs) ... services in order to deal with a 92 percent ... fee) from $6.25 to $12.01 per bed per day, ... the average facility will pay an additional $17,520 to ... a total tax of $438,365 yearly. ,, Nearly 96 ...

Breaking Medicine News(10 mins):Health News:Synthetic Red Blood Cells Developed 2 Health News:Synthetic Red Blood Cells Developed 3 Health News:Americold Realty Trust Files Registration Statement for Proposed Initial Public Offering 2 Health News:NORD Calls for Immediate End to Lifetime Insurance Caps 2 Health News:Cutting TV Time Burns More Calories 2 Health News:Survey Shows Tax Increase Forcing Ohio Skilled Nursing Facilities to Make Cuts 2 Health News:Survey Shows Tax Increase Forcing Ohio Skilled Nursing Facilities to Make Cuts 3

[0] Synthetic Red Blood Cells Developed [0] Americold Realty Trust Files Registration Statement for Proposed Initial Public Offering [0] NORD Calls for Immediate End to Lifetime Insurance Caps [0] Cutting TV Time Burns More Calories [1] Survey Shows Tax Increase Forcing Ohio Skilled Nursing Facilities to Make Cuts

... Journal of Occupational and Environmental Medicine, Investigates Relationship of Co-payments, ... ... Utilization, PHILADELPHIA, May 12 High prescription drug,co-payments are ... to a new study published this month in the,Journal of ...

... it has long been known that embryonic stem cells ... tissue-specific cells, the exact mechanism as to how this ... the Hebrew University of Jerusalem and elsewhere have succeeded ... as to whether the stem cells achieve their development ...

... think before they drink as part of a research project ... of health psychologists at The University of Nottingham plan to ... health effects of binge drinking and asking employees for a ... single session could change peoples binge drinking behaviour in the ...

... ULURU Inc. (Amex: ULU ),today reported financial results ... the quarter ended March 31, 2008, the net loss ... compared to a net,loss of $847,000, or $0.01 per ... 2008 net loss was impacted by non-cash expenses of,$497,000, ...

... mutated gene has been discovered as the key behind ... new research at Adelaides Womens & Childrens Hospital and ... published today in Nature Genetics, shows that although men ... The research has been led by Dr Leanne Dibbens ...

... look more attractive. Fish diet to avoid being beaten ... eaten as a result. , That is the fascinating conclusion ... the ARC Centre of Excellence for Coral Reef Studies and ... , The same team who recently revealed fish use the ...

Other Medicine News:Health News:New Study Shows Lowering Co-payments Can Lead to Lower Total Healthcare Costs, Improved Overall Health 2 Health News:New Study Shows Lowering Co-payments Can Lead to Lower Total Healthcare Costs, Improved Overall Health 3 Health News:New Study Shows Lowering Co-payments Can Lead to Lower Total Healthcare Costs, Improved Overall Health 4 Health News:New Study Shows Lowering Co-payments Can Lead to Lower Total Healthcare Costs, Improved Overall Health 5 Health News:How embryonic stem cells develop into tissue-specific cells demonstrated 2 Health News:Think before you drink, says university research 2 Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 2 Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 3 Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 4 Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 5 Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 6 Health News:Mutant gene causes epilepsy, intellectual disability in women 2 Health News:Fish diet to avoid fights 2

New Study Shows Lowering Co-payments Can Lead to Lower Total Healthcare Costs, Improved Overall Health How embryonic stem cells develop into tissue-specific cells demonstrated Think before you drink, says university research ULURU Inc. Reports First Quarter 2008 Financial Results Mutant gene causes epilepsy, intellectual disability in women Fish diet to avoid fights

Flat tip, bare fiber, no cooling, polished SMA 905, 3 meters long. Sold in boxes of five. Each part is individually packaged in sterile Tyvek bags....

... unique lateral fiber possessing a ... rotated to any one of ... fibers in one. The fiber ... and coagulation and back to ...

... Ultrafin™ Stirrup is the latest ... stirrup features a roomier boot ... up to an 800 pound ... to position heavy legs more ...

... assist stirrups are designed to travel a full ... They lock tight wherever you release the rotating ... are done at the handle with no need ... socket. The rotation of system was designed to ...

Medicine Products:

Megabeam Non-Contact Fibers for Holmium Lasers QuadraLase™Ultrafin™ Stirrup Lift Assist Stirrup System

Replidyne's Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium...(eases. Inpreclinical studies REP3123 has...),Health